It functions by stimulating the growth of megakaryocytes, which are bone marrow cells responsible for platelet production. An autoimmune disorder, ITP leads to lower platelet counts, causing an ...

The therapy is also being reviewed in the European Union (EU), China and the US for immune thrombocytopenia (ITP). The FDA has set a target action date of 29 August 2025 for its decision on ITP ...